Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Lymphoid 1

Interventions

fludarabine 7Busulfan 6fludarabine phosphate 4Melphalan 4Whole-Body Irradiation 3Tacrolimus 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Cyclophosphamide 3thymoglobulin 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Bone Marrow Transplantation 2Behavior Therapy 2tozasertib 1sargramostim 1Thiotepa 1Stem Cell Transplantation 1Sirolimus 1RFT5-SMPT-dgA immunotoxin 1Photopheresis 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Dasatinib 1Cyclosporins 1Cyclosporine 1Colony-Stimulating Factors 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphoid × tozasertib × Myeloid × Clear all
NCT00111683 2015-08-25

MK0457 in Patients With Leukemia (0457-003)

Merck Sharp & Dohme LLC

Phase 1 Completed
28 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Lymphoid, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡